---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Long-term morbidity"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Long-term morbidity. Topics: Physical comorbidity: incident cardiovascular and metabolic disease; Cardiovascular events: major adverse cardiovascular events in Swedish registers; Psychiatric comorbidity: Stockholm MDD cohort; Comorbidity, obesity, and disability: Canadian primary care; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Physical comorbidity: incident cardiovascular and metabolic disease

> “It is well established that TRD populations have a higher rate of psychiatric and physical comorbidities as compared to non‐TRD populations 143 . In addition, TRD is a risk factor for incident physical comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, osteoporosis, and metabolic syndrome”
> “For example, it is established that MDD is a risk factor for cardiovascular disease, obesity and type 2 diabetes mellitus, and this is especially apparent in individuals with more severe and/or persistent depressive syndromes, which are over‐represented in TRD populations”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.7-2"></a>

### Cardiovascular events: major adverse cardiovascular events in Swedish registers

> “We identified 143,731 patients with depression, including 23,335 with TRD and 45,217 with severe depression. Patients with depression had a higher hazard of MACE vs comparators (aHR 1.50, 95%CI 1.40-1.62). Hazards of MACE were overall similar in patients with TRD vs comparators (aHR 1.06, 95%CI 0.93-1.22) and severe depression vs comparators (aHR 1.04, 95%CI 0.96-1.13). Analyzing separate outcomes, patients with TRD had a higher hazard of cardiovascular death (aHR 1.32, 95 %CI 1.03-1.69).”
> “Patients with TRD or severe depression are not at additional overall risk of MACE compared to other depressed patients. However, an additional risk may exist in younger patients with severe depression and specifically of cardiovascular death in patients with TRD.”

Source: [Nygren et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381860/)

<a id="topic-2.2.1.7-3"></a>

### Psychiatric comorbidity: Stockholm MDD cohort

> “In patients with TRD, we observed a gradual increase in the prevalence of all psychiatric comorbid diagnoses during the year preceding the TRD index date, most pronounced for anxiety and stress (60% and 36%, respectively)”
> “Table 1 also shows an increased prevalence for sleep disorders, substance abuse, personality disorders, and intentional self-harm in patients with TRD.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.7-4"></a>

### Comorbidity, obesity, and disability: Canadian primary care

> “Higher rates of disability and comorbidity (axes I to III) were associated with treatment resistance. Obesity and being overweight were also associated with treatment resistance.”

Source: [Rizvi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086317/)

<a id="topic-2.2.1.7-5"></a>

### Work disability: lost workdays in the Stockholm MDD cohort

> “Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.”

Source: [Lundberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9856735/)

<a id="topic-2.2.1.7-6"></a>

### Quality of life and functional disability under usual care

> “The SF-36 indicated globally poor quality of life in this sample.”

Source: [Dunner et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16841617/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
